Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, age at diagnosis 18 years and older~* Histologically confirmed unilateral primary invasive carcinoma of the breast~* Patients must qualify for neoadjuvant treatment as follows:~  * No clinical evidence for distant metastasis (M0)~ * Clinical cT1c-T4a-c (participation of patients with tumors \> cT2 is strongly recommended) and no evidence for distant metastases (M0)~ * All clinical N (participation of patients with cN+, also in case of cT1c, is strongly recommended)~ * Known positive HR-status and centrally confirmed HER2+-status by IHC/FISH~ * Patients need to fulfill adequate blood count and organ function to receive chemotherapy (see exclusion criteria).~* Tumor block available for central pathology review~* Performance Status ECOG ≤ 1 or KI ≥ 80%~* Negative pregnancy test (urine or serum) within 7 days prior to registration in premenopausal patients~* Patients of childbearing potential must accept to implement a highly effective (less than 1% failure rate according to Pearl index) non-hormonal contraceptive measures during the study treatment and for 6 months following the last dose of study treatment (trastuzumab and pertuzumab) such as:~  * Intrauterine device (IUD)~ * bilateral tubal occlusion~ * vasectomised partner~ * sexual abstinence~* Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements~* The patient must be accessible for treatment and follow-up~* LVEF \> 55%; LVEF within normal limits of each institution measured by echocardiography (within 42 days prior to randomization)~* Normal ECG (within 42 days prior to randomization)~Exclusion Criteria:~* Known hypersensitivity reaction to the compounds or incorporated substances~* Prior malignancy with a disease-free survival of \< 10 years, except curatively treated basalioma of the skin, pTis of the cervix uteri~* Non-operable breast cancer including inflammatory breast cancer~* Previous or concurrent treatment with cytotoxic agents for any reason~* Concurrent treatment with other experimental drugs and participation in another clinical trial or clinical research project within 30 days prior to study entry is excluded~* Male breast cancer~* Concurrent pregnancy~* Breastfeeding~* Sequential breast cancer~* Reasons indicating risk of poor compliance~* Known polyneuropathy ≥ grade 2~* Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including but not confined to:~  * Uncompensated chronic heart failure or systolic dysfunction (LVEF \< 55%, CHF NYHA classes II-IV),~ * unstable arrhythmias requiring treatment i.e., atrial tachycardia with a heart rate ≥ 100/min at rest, significant ventricular arrhythmia (ventricular tachycardia) or higher-grade AV-block,~ * Angina pectoris within the last 6 months requiring anti-anginal medication,~ * Clinically significant valvular heart disease,~ * Evidence of myocardial infarction on electrocardiogram (ECG),~ * Poorly controlled hypertension (e.g., systolic \> 180 mm Hg or diastolic \> 100 mm Hg).~* Inadequate organ function including but not confined to:~  * hepatic impairment (Child Pugh Class C)~ * pulmonary disease (severe dyspnea at rest requiring oxygen therapy)~* Abnormal blood values:~  * Thrombocytopenia \> CTCAE grade 1~ * Increases in ALT/AST \> CTCAE grade 1~ * Hypokalaemia \> CTCAE grade 1~ * Neutropenia \> CTCAE grade 1~ * Anaemia \> CTCAE grade 1

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel+Trastuzumab+Pertuzumab (Type: ACTIVE_COMPARATOR): Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.~Adjuvant Therapy: Standard of care
- Endocrine+Trastuzumab+Pertuzumab (Type: EXPERIMENTAL): Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.~Adjuvant Therapy: Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete